Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 3 Clear all

Conditions: Polycystic Ovary Syndrome, Healthy, Anovulation, Hyperandrogenism
Interventions: Recombinant Follicle Stimulating Hormone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Solid Tumor
Interventions: BS006 Injection; Drug
Lead sponsor: Binhui Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Detroit, Michigan

Conditions: Anesthesia
Interventions: Dural puncture epidurals (DPE), Traditional epidurals (EPI), Combined-spinal epidural technique (CSE); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Bardstown, Kentucky • Metairie, Louisiana

Conditions: Pancreatic Cancer
Interventions: Enzalutamide, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Geographic Atrophy
Interventions: ACU-4429, Placebo; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Hepatic Impairment, Healthy Participants
Interventions: MK-8527; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Brain Metastases
Interventions: brain metastases radiosurgery; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Infections, Bacterial
Interventions: GSK2140944 (Single dose), GSK2140944 (Multiple dose); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myasthenia Gravis
Interventions: UCB7665, Placebo; Drug · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 3 more

Conditions: Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions: Ruxolitinib, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Patritumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Newnan, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 39
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more

Conditions: Sepsis
Interventions: personalized dosing adjustment of vancomycin; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: Ethambutol, Rifampin, Azithromycin, Pancrelipase; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Interventions: casdatifan, Cabozantinib, Zimberelimab, Ipilimumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more

Conditions: COVID-19 Prevention
Interventions: Ad26.COV2.S; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,609 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more

Conditions: Epilepsy
Interventions: VX-765 Part A, Placebo, VX-765 Part B; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 22
States / cities: Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.222; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 4,328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 48
States / cities: Banning, California • La Mesa, California • Lake Worth, Florida + 41 more

Conditions: Breast Cancer
Interventions: TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more

Conditions: Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions: PDA-002, Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Garden Grove, California • Orange, California • Orlando, Florida + 4 more

Conditions: Alcohol Use Disorder (AUD), Alcohol Drinking
Interventions: Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate", FDG; Dietary Supplement · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

Epidural Technique: Does it Really Matter to the Patient?

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder